Amitabh Chak1, Navtej S Buttar2, Nathan R Foster3, Drew K Seisler3, Norman E Marcon4, Robert Schoen5, Marcia R Cruz-Correa6, Gary W Falk7, Prateek Sharma8, Chin Hur9, David A Katzka2, Luz M Rodriguez10, Ellen Richmond10, Anamay N Sharma2, Thomas C Smyrk11, Sumithra J Mandrekar3, Paul J Limburg2. 1. Department of Gastroenterology and Hepatology, University Hospitals Case Medical Center, Cleveland, Ohio. Electronic address: amitabh.chak@UHhospitals.org. 2. Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. 3. Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota. 4. Department of Medicine, Gastroenterology, St Michael's Hospital, Toronto, Ontario, Canada. 5. Department of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh, Pittsburgh, Pennsylvania. 6. Department of Gastroenterology Oncology at UPR Cancer Center, University of Puerto Rico, San Juan, Puerto Rico. 7. Department of Gastroenterology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 8. Department of Gastroenterology, Hepatology and Motility, Kansas City VA, Kansas City, Missouri. 9. Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. 10. Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 11. Department of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND & AIMS: Obesity is associated with neoplasia, possibly via insulin-mediated cell pathways that affect cell proliferation. Metformin has been proposed to protect against obesity-associated cancers by decreasing serum insulin. We conducted a randomized, double-blind, placebo-controlled, phase 2 study of patients with Barrett's esophagus (BE) to assess the effect of metformin on phosphorylated S6 kinase (pS6K1), a biomarker of insulin pathway activation. METHODS:Seventy-four subjects with BE (mean age, 58.7 years; 58 men [78%; 52 with BE >2 cm [70%]) were recruited through 8 participating organizations of the Cancer Prevention Network. Participants were randomly assigned to groups given metformin daily (increasing to 2000 mg/day by week 4, n = 38) or placebo (n = 36) for 12 weeks. Biopsy specimens were collected at baseline and at week 12 via esophagogastroduodenoscopy. We calculated and compared percent changes in median levels of pS6K1 between subjects given metformin vs placebo as the primary end point. RESULTS: The percent change in median level of pS6K1 did not differ significantly between groups (1.4% among subjects given metformin vs -14.7% among subjects given placebo; 1-sided P = .80). Metformin was associated with an almost significant reduction in serum levels of insulin (median -4.7% among subjects given metformin vs 23.6% increase among those given placebo, P = .08) as well as in homeostatic model assessments of insulin resistance (median -7.2% among subjects given metformin vs 38% increase among those given placebo, P = .06). Metformin had no effects on cell proliferation (on the basis of assays for KI67) or apoptosis (on the basis of levels of caspase 3). CONCLUSIONS: In a chemoprevention trial of patients with BE, daily administration of metformin for 12 weeks, compared with placebo, did not cause major reductions in esophageal levels of pS6K1. Although metformin reduced serum levels of insulin and insulin resistance, it did not discernibly alter epithelial proliferation or apoptosis in esophageal tissues. These findings do not support metformin as a chemopreventive agent for BE-associated carcinogenesis. ClinicalTrials.gov number, NCT01447927.
RCT Entities:
BACKGROUND & AIMS:Obesity is associated with neoplasia, possibly via insulin-mediated cell pathways that affect cell proliferation. Metformin has been proposed to protect against obesity-associated cancers by decreasing serum insulin. We conducted a randomized, double-blind, placebo-controlled, phase 2 study of patients with Barrett's esophagus (BE) to assess the effect of metformin on phosphorylated S6 kinase (pS6K1), a biomarker of insulin pathway activation. METHODS: Seventy-four subjects with BE (mean age, 58.7 years; 58 men [78%; 52 with BE >2 cm [70%]) were recruited through 8 participating organizations of the Cancer Prevention Network. Participants were randomly assigned to groups given metformin daily (increasing to 2000 mg/day by week 4, n = 38) or placebo (n = 36) for 12 weeks. Biopsy specimens were collected at baseline and at week 12 via esophagogastroduodenoscopy. We calculated and compared percent changes in median levels of pS6K1 between subjects given metformin vs placebo as the primary end point. RESULTS: The percent change in median level of pS6K1 did not differ significantly between groups (1.4% among subjects given metformin vs -14.7% among subjects given placebo; 1-sided P = .80). Metformin was associated with an almost significant reduction in serum levels of insulin (median -4.7% among subjects given metformin vs 23.6% increase among those given placebo, P = .08) as well as in homeostatic model assessments of insulin resistance (median -7.2% among subjects given metformin vs 38% increase among those given placebo, P = .06). Metformin had no effects on cell proliferation (on the basis of assays for KI67) or apoptosis (on the basis of levels of caspase 3). CONCLUSIONS: In a chemoprevention trial of patients with BE, daily administration of metformin for 12 weeks, compared with placebo, did not cause major reductions in esophageal levels of pS6K1. Although metformin reduced serum levels of insulin and insulin resistance, it did not discernibly alter epithelial proliferation or apoptosis in esophageal tissues. These findings do not support metformin as a chemopreventive agent for BE-associated carcinogenesis. ClinicalTrials.gov number, NCT01447927.
Authors: Siddharth Singh; Anamay N Sharma; Mohammad Hassan Murad; Navtej S Buttar; Hashem B El-Serag; David A Katzka; Prasad G Iyer Journal: Clin Gastroenterol Hepatol Date: 2013-05-22 Impact factor: 11.382
Authors: Jose M Garcia; Andres E Splenser; Jennifer Kramer; Abeer Alsarraj; Stephanie Fitzgerald; David Ramsey; Hashem B El-Serag Journal: Clin Gastroenterol Hepatol Date: 2013-08-15 Impact factor: 11.382
Authors: Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen Journal: Gastroenterology Date: 2011-03 Impact factor: 22.682
Authors: Anna Mokrowiecka; Piotr Daniel; Anna Jasinska; Miroslawa Pietruczuk; Maciej Pawlowski; Piotr Szczesniak; Daria Orszulak-Michalak; Ewa Malecka-Panas Journal: Hepatogastroenterology Date: 2012 Nov-Dec
Authors: Gary W Falk; Navtej S Buttar; Nathan R Foster; Katie L Allen Ziegler; Catherine J Demars; Yvonne Romero; Norman E Marcon; Thomas Schnell; Douglas A Corley; Prateek Sharma; Marcia R Cruz-Correa; Chin Hur; David E Fleischer; Amitabh Chak; Kenneth R Devault; David S Weinberg; Gary Della'Zanna; Ellen Richmond; Thomas C Smyrk; Sumithra J Mandrekar; Paul J Limburg Journal: Gastroenterology Date: 2012-07-11 Impact factor: 22.682
Authors: Brandy M Heckman-Stoddard; Andrea DeCensi; Vikrant V Sahasrabuddhe; Leslie G Ford Journal: Diabetologia Date: 2017-08-03 Impact factor: 10.122
Authors: Bhaskar Banerjee; Nicholas J Shaheen; Jessica A Martinez; Chiu-Hsieh Hsu; Eugene Trowers; Blake A Gibson; Gary Della'Zanna; Ellen Richmond; H-H Sherry Chow Journal: Cancer Prev Res (Phila) Date: 2016-02-23
Authors: Jason A Zell; Christine E McLaren; Timothy R Morgan; Michael J Lawson; Sherif Rezk; C Gregory Albers; Wen-Pin Chen; Joseph C Carmichael; Jinah Chung; Ellen Richmond; L M Rodriguez; Eva Szabo; Leslie G Ford; Michael N Pollak; Frank L Meyskens Journal: Cancer Prev Res (Phila) Date: 2019-12-09
Authors: Brandy M Heckman-Stoddard; Sara Gandini; Matteo Puntoni; Barbara K Dunn; Andrea DeCensi; Eva Szabo Journal: Semin Oncol Date: 2015-09-08 Impact factor: 4.929